INTERNATIONAL PHARMACEUTICAL AEROSOL CONSORTIUM

Lobbying Spend

—

Filings

Firms Hired

Active Period

2007–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	4	1
2015	—	4	1
2014	—	4	1
2013	—	5	1
2012	—	4	1
2011	—	4	1
2010	—	4	1
2009	—	4	1
2008	—	4	1
2007	—	4	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FAEGRE DRINKER BIDDLE & REATH LLP	—	80

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
Environmental Protection Agency (EPA)	17
HOUSE OF REPRESENTATIVES	17
Food & Drug Administration (FDA)	16
SENATE	11
State, Dept of (DOS)	11

Most frequently reported lobbying issues

Issue Code	Description	Reports
Environment/Superfund	Environment/Superfund	30
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

S. 2657116th Congress

AGILE Act of 2019

Cited source text and reported amounts

S. 2657, Advanced Geothermal Innovation Leadership Act of 2019.

Client expense: — · Firm income: —

Matched citations: S. 2657

INTERNATIONAL PHARMACEUTICAL AEROSOL CONSORTIUM — Lobbying Disclosure | Poliscope